Journalist Richard Fisher is among a 10,000-person cohort participating in a clinical trial of a SARS-CoV-2 vaccine candidate developed at the University of Oxford and based on a weakened chimpanzee adenovirus. The process has not been quick, easy or worry-free, and there's no guarantee that at the end of the trial, the vaccine will have been proven effective, which is something the public and many politicians don't understand about vaccine development, Fisher writes.
COVID-19 vaccine trial participant describes the process
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.